Detalhe da pesquisa
1.
Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.
Haematologica
; 104(3): 497-504, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30287621
2.
Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion.
Blood
; 127(6): 749-60, 2016 Feb 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-26626993
3.
Time-dependent changes in mortality and transformation risk in MDS.
Blood
; 128(7): 902-10, 2016 08 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-27335276
4.
Prospective evaluation of the effect of deferasirox on hematologic response in transfusion-dependent patients with low-risk MDS and iron overload.
Eur J Haematol
; 2018 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29719933
5.
A randomized phase II trial of azacitidine +/- epoetin-ß in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.
Haematologica
; 101(8): 918-25, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27229713
6.
BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.
Blood
; 122(18): 3169-77, 2013 Oct 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-24047651
7.
Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities.
Am J Hematol
; 90(10): 859-63, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26113240
8.
Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes.
Blood
; 119(6): 1532-42, 2012 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-22160620
9.
Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.
Blood
; 119(14): 3211-8, 2012 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-22343920
10.
Revised international prognostic scoring system for myelodysplastic syndromes.
Blood
; 120(12): 2454-65, 2012 Sep 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-22740453
11.
Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group.
Haematologica
; 99(1): 46-53, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23975179
12.
Azacitidine in untreated acute myeloid leukemia: a report on 149 patients.
Am J Hematol
; 89(4): 410-6, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24375487
13.
High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study.
Br J Haematol
; 162(2): 240-9, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23692641
14.
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.
Blood
; 118(14): 3824-31, 2011 Oct 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-21828134
15.
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.
Blood
; 117(2): 403-11, 2011 Jan 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-20940414
16.
Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes.
Blood
; 128(16): 2096-2097, 2016 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-27535995
17.
Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire.
Eur J Haematol
; 90(5): 355-64, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23320648
18.
Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM.
Br J Haematol
; 158(2): 232-237, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22571447
19.
Mutation in TET2 in myeloid cancers.
N Engl J Med
; 360(22): 2289-301, 2009 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-19474426
20.
IκB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia.
Blood
; 116(20): 4240-50, 2010 Nov 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-20671123